News and events

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. The goal of the IMI 2 is to develop next generation vaccines, medicines and treatments, such as new antibiotics. IMI 2 will start in 2014 and will run for 10 years. IMI 2 aims to deliver: a 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years; new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease.

The following topics are under consideration for inclusion in the Calls for proposals that will be launched in 2014 under IMI 2 (Call1):

  • Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)
  • Discovery and validation of novel endpoints in retinal diseases

Future topics - IMI 2 2014:

  • RADAR: Remote assessment of disease and relapse

Further information:

© 2013 BioTalentum Ltd. All rights reserved.